Cherepakhin Olga S, Argenyi Zsolt B, Moshiri Ata S
School of Medicine, University of Washington, Seattle, WA 98195, USA.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Cancers (Basel). 2021 Dec 28;14(1):123. doi: 10.3390/cancers14010123.
Melanoma is a deadly skin cancer with rapidly increasing incidence worldwide. The discovery of the genetic drivers of melanomagenesis in the last decade has led the World Health Organization to reclassify melanoma subtypes by their molecular pathways rather than traditional clinical and histopathologic features. Despite this significant advance, the genomic and transcriptomic drivers of metastatic progression are less well characterized. This review describes the known molecular pathways of cutaneous and uveal melanoma progression, highlights recently identified pathways and mediators of metastasis, and touches on the influence of the tumor microenvironment on metastatic progression and treatment resistance. While targeted therapies and immune checkpoint blockade have significantly aided in the treatment of advanced disease, acquired drug resistance remains an unfortunately common problem, and there is still a great need to identify potential prognostic markers and novel therapeutic targets to aid in such cases.
黑色素瘤是一种致命的皮肤癌,在全球范围内发病率迅速上升。过去十年间黑色素瘤发生的基因驱动因素的发现,促使世界卫生组织根据分子途径而非传统的临床和组织病理学特征对黑色素瘤亚型进行重新分类。尽管取得了这一重大进展,但转移性进展的基因组和转录组驱动因素仍不太清楚。这篇综述描述了皮肤和葡萄膜黑色素瘤进展的已知分子途径,强调了最近确定的转移途径和介质,并探讨了肿瘤微环境对转移进展和治疗耐药性的影响。虽然靶向治疗和免疫检查点阻断在晚期疾病的治疗中发挥了显著作用,但获得性耐药仍然是一个不幸的常见问题,仍然非常需要确定潜在的预后标志物和新的治疗靶点来帮助解决此类情况。